ClinicalTrials.gg
Sign In

Shock, Cardiogenic clinical trials

The registry lists 296 studies for Shock, Cardiogenic across more than 10 countries. 134 are recruiting or about to start. 221 of them are mainly about Shock, Cardiogenic (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-09.

Get an email when these change. Save the Shock, Cardiogenic studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Recruiting
102
Completed
89
Status unknown
47
Not yet recruiting
30
Terminated
11
Active, not recruiting
9

Phase

Phase 4
23
Phase 2
18
Phase 3
16
Phase 1
4
Early Phase 1
1

Where

France
62
United States
49
Germany
36
China
20
Italy
20
Canada
13

Who runs them

Central Hospital, Nancy, France (12) · Assistance Publique - Hôpitaux de Paris (8) · Beijing Anzhen Hospital (7) · University Hospital, Montpellier (7) · Samsung Medical Center (6) · Abiomed Inc. (6) · University Hospital, Strasbourg, France (5) · National Taiwan University Hospital (4)

What is being tested here

Drugs under test in Shock, Cardiogenic studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Milrinone203
Ivabradine125
Dobutamine114
Simendan134
Istaroxime113
Cangrelor102
Esmolol102
Norepinephrine112
Heparin102
6α-methylprednisone101

Coming up

5phase 3 studies under way
48studies finish main data collection within a year3 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 102 Shock, Cardiogenic studies recruiting now, 70 (69%) set no upper age limit and 9 (9%) stop at 75 or younger. 11 (11%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (2%) take healthy volunteers.

Recruiting studies that take each age, of 102
AgeWomenMen
1011 (11%)11 (11%)
1893 (91%)93 (91%)
30100 (98%)100 (98%)
40101 (99%)101 (99%)
50101 (99%)101 (99%)
65100 (98%)100 (98%)
7598 (96%)98 (96%)
8579 (77%)79 (77%)

Across all 296 studies, recruiting or not: 11% stop at 75 or younger and 3% at 65; 10% take children; 1% are for women only and 0% for men only; 3% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Shock, Cardiogenic studies take

Of 84 observational studies under Shock, Cardiogenic, half reached primary completion within 45 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Interventional, no phase39 mo24–55 · 53 studies—39 mo24–55 · 49 studies
Observational45 mo24–… · 84 studies—44 mo19–… · 79 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 13, 2026.

Started recruiting6

Show 1 more

Newly registered1

Studies

Recruiting first, then most recently updated. Showing 50 of 296. Browse all 296 → or search them.